ArticleFunctional & integrative genomics2026
MYC-driven TRIM27 upregulation promotes prostate cancer progression by enhancing CANX ubiquitination and activating PI3K/AKT signaling.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
One of the most prevalent malignant tumors in the male genitourinary system is prostate cancer (PCa). The health of men is seriously threatened by the lack of appropriate treatment options for advanced prostate cancer. As E3 ubiquitin ligases, the TRIM family is essential for the development and spread of tumors. Of them, TRIM27 plays a crucial role as a fundamental member of the TRIM family. The tumor immune microenvironment was closely linked to high expression of TRIM27, which was found to be an independent risk factor for a poor prognosis in PCa. Additional in vitro tests verified that TRIM27 stimulates the growth of tumors by controlling the expression of CANX by ubiquitination through triggering the PI3K/AKT signaling pathway. In the meantime, we used several transcription factor databases to find the transcription factor MYC, which can bind to the TRIM27 promoter region and increase its expression, in order to investigate the upstream regulators of TRIM27. In conclusion, our results show that MYC-regulated TRIM27 upregulation influences cancer development through CANX, offering new therapeutic targets and avenues for investigation in the detection and management of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.